Introduction We aimed to study the survival outcomes in women diagnosed with low grade serous carcinoma of Ovary (LGSC) with respect to their clinicopathological and molecular profile, treatment modalities.

Methods The molecular and immunohistochemistry profiling with KRAS, BRAF, ER, PR and p53 status of the archived paraffin blocks of 26 patients with low grade serous cancers from 1st January 2014 to 31st December 2022 was performed. Correlation of the above markers with clinical profile and survival outcome was analyzed.

Results Patients with LGSC constituted 2% of the patients with ovarian cancer treated during this period with a mean age of 38(SD-12.3), mean CA 125 of 268 IU/ml (range 51-1193), the mean PCI was 3 (0-9) and 43.3% had IIIC and above disease. Amongst the 88% who underwent primary debulking surgery, R0 was obtained in 73%. Adjuvant chemotherapy was given in 42% while hormonal therapy was offered in 31%. The hormonal receptor status was ER positive in 80%, PR positive in 76% whereas only wild type positive in 78.3% and inconclusive in 19.2%. Recurrence was seen in 5(19.2%) and death in 2 (7.7%) with median RFS of 75 months and OFS of 88 months. Survival was not related to any of the clinical or molecular profiles on the cox regression analysis.

Conclusion/Implications Molecular profiling and immunohistochemistry play a vital role in the diagnosis of the low grade serous cancers and aid in the decision making of adjuvant therapy with hormonal and targetted agents.